JP2020530837A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530837A5 JP2020530837A5 JP2020505344A JP2020505344A JP2020530837A5 JP 2020530837 A5 JP2020530837 A5 JP 2020530837A5 JP 2020505344 A JP2020505344 A JP 2020505344A JP 2020505344 A JP2020505344 A JP 2020505344A JP 2020530837 A5 JP2020530837 A5 JP 2020530837A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- optionally substituted
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 208000016588 Idiopathic hypersomnia Diseases 0.000 claims 3
- 206010041349 Somnolence Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- 208000001573 Cataplexy Diseases 0.000 claims 2
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 208000025748 atypical depressive disease Diseases 0.000 claims 2
- -1 cyano, hydroxy Chemical group 0.000 claims 2
- 150000001923 cyclic compounds Chemical class 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 201000003631 narcolepsy Diseases 0.000 claims 2
- 208000001797 obstructive sleep apnea Diseases 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 201000002859 sleep apnea Diseases 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 125000005309 thioalkoxy group Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 208000032140 Sleepiness Diseases 0.000 claims 1
- 208000014679 binge eating disease Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 229940125904 compound 1 Drugs 0.000 claims 1
- 229940125782 compound 2 Drugs 0.000 claims 1
- 229940126214 compound 3 Drugs 0.000 claims 1
- 229940125898 compound 5 Drugs 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 230000037321 sleepiness Effects 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 0 *C(*=CCCC(CC(C=C1)=CC=C*1N)N)=O Chemical compound *C(*=CCCC(CC(C=C1)=CC=C*1N)N)=O 0.000 description 4
- QKLNKMCPBIMCFA-SNVBAGLBSA-N C#C[C@H](Cc1ccccc1)CNC(N)=O Chemical compound C#C[C@H](Cc1ccccc1)CNC(N)=O QKLNKMCPBIMCFA-SNVBAGLBSA-N 0.000 description 1
- QVGUHAJLRXKMPW-UHFFFAOYSA-N NC(CCC(N)=O)Cc1ccccc1 Chemical compound NC(CCC(N)=O)Cc1ccccc1 QVGUHAJLRXKMPW-UHFFFAOYSA-N 0.000 description 1
- FTNJLXWGUJIQJU-UHFFFAOYSA-N NC(Cc1ccccc1)CNC(N)=O Chemical compound NC(Cc1ccccc1)CNC(N)=O FTNJLXWGUJIQJU-UHFFFAOYSA-N 0.000 description 1
- DWQSYLXJTGXCPA-UHFFFAOYSA-N NC(Cc1ccccc1)CNCCC=O Chemical compound NC(Cc1ccccc1)CNCCC=O DWQSYLXJTGXCPA-UHFFFAOYSA-N 0.000 description 1
- JQJQAUWFQZKYGJ-UHFFFAOYSA-N NC(Cc1ccccc1)COC(N)=S Chemical compound NC(Cc1ccccc1)COC(N)=S JQJQAUWFQZKYGJ-UHFFFAOYSA-N 0.000 description 1
- OYQPYDYOLYVFAR-UHFFFAOYSA-N NC(Cc1ccccc1)COS(N)(=O)=O Chemical compound NC(Cc1ccccc1)COS(N)(=O)=O OYQPYDYOLYVFAR-UHFFFAOYSA-N 0.000 description 1
- MACBUKJAOPIHLV-UHFFFAOYSA-N NC(Cc1ccccc1)CSC(N)=O Chemical compound NC(Cc1ccccc1)CSC(N)=O MACBUKJAOPIHLV-UHFFFAOYSA-N 0.000 description 1
- UHGCADOIJMYQPL-GFKGLTBGSA-N N[C@@H](CC=C=CC(N)=O)Cc1ccccc1 Chemical compound N[C@@H](CC=C=CC(N)=O)Cc1ccccc1 UHGCADOIJMYQPL-GFKGLTBGSA-N 0.000 description 1
- JQJQAUWFQZKYGJ-SECBINFHSA-N N[C@H](Cc1ccccc1)COC(N)=S Chemical compound N[C@H](Cc1ccccc1)COC(N)=S JQJQAUWFQZKYGJ-SECBINFHSA-N 0.000 description 1
- OYQPYDYOLYVFAR-SECBINFHSA-N N[C@H](Cc1ccccc1)COS(N)(=O)=O Chemical compound N[C@H](Cc1ccccc1)COS(N)(=O)=O OYQPYDYOLYVFAR-SECBINFHSA-N 0.000 description 1
- MACBUKJAOPIHLV-SECBINFHSA-N N[C@H](Cc1ccccc1)CSC(N)=O Chemical compound N[C@H](Cc1ccccc1)CSC(N)=O MACBUKJAOPIHLV-SECBINFHSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023072520A JP7642707B2 (ja) | 2017-07-31 | 2023-04-26 | カルバモイルフェニルアラニノール類縁体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762539088P | 2017-07-31 | 2017-07-31 | |
| US62/539,088 | 2017-07-31 | ||
| PCT/US2018/044465 WO2019027941A1 (en) | 2017-07-31 | 2018-07-31 | CARBAMOYL PHENYLALANINOL ANALOGUES AND USES THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023072520A Division JP7642707B2 (ja) | 2017-07-31 | 2023-04-26 | カルバモイルフェニルアラニノール類縁体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530837A JP2020530837A (ja) | 2020-10-29 |
| JP2020530837A5 true JP2020530837A5 (https=) | 2021-07-26 |
| JP7366002B2 JP7366002B2 (ja) | 2023-10-20 |
Family
ID=65233074
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505344A Active JP7366002B2 (ja) | 2017-07-31 | 2018-07-31 | カルバモイルフェニルアラニノール類縁体およびその使用 |
| JP2023072520A Active JP7642707B2 (ja) | 2017-07-31 | 2023-04-26 | カルバモイルフェニルアラニノール類縁体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023072520A Active JP7642707B2 (ja) | 2017-07-31 | 2023-04-26 | カルバモイルフェニルアラニノール類縁体およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11413264B2 (https=) |
| EP (1) | EP3661911A4 (https=) |
| JP (2) | JP7366002B2 (https=) |
| KR (1) | KR102643275B1 (https=) |
| CN (1) | CN111094238B (https=) |
| AU (1) | AU2018312328B2 (https=) |
| CA (1) | CA3071779A1 (https=) |
| MX (2) | MX2020001146A (https=) |
| RU (1) | RU2020108634A (https=) |
| SA (1) | SA520411187B1 (https=) |
| SG (1) | SG11202000817SA (https=) |
| WO (1) | WO2019027941A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| KR102643275B1 (ko) * | 2017-07-31 | 2024-03-04 | 재즈 파마슈티칼즈 아일랜드 리미티드 | 카바모일 페닐알라니놀 유사체 및 이의 용도 |
| EP3930702A1 (en) | 2019-03-01 | 2022-01-05 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| AU2023281731A1 (en) * | 2022-06-03 | 2024-12-19 | Axsome Therapeutics | Carbamoyl phenylalaninol compounds as taar1 agonists |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2604434B1 (fr) * | 1986-09-29 | 1989-05-19 | Inst Nat Sante Rech Med | Derives d'amino-2 ethanethiol, leur preparation et leur application en therapeutique |
| KR100197892B1 (ko) | 1994-09-09 | 1999-06-15 | 남창우 | 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법 |
| US5756817C1 (en) | 1995-02-11 | 2001-04-17 | Sk Corp | O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same |
| KR0173862B1 (ko) | 1995-02-11 | 1999-04-01 | 조규향 | O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| KR0173863B1 (ko) | 1995-04-10 | 1999-04-01 | 조규향 | 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| EP0873308B1 (en) * | 1996-10-10 | 2002-01-02 | SK Corporation | O-carbamoyl-phenylalaninol compounds and their pharmaceutically useful salts |
| WO1998017636A1 (en) * | 1996-10-22 | 1998-04-30 | Ortho Pharmaceutical Corporation | Phenylalaninol derivatives for the treatment of central nervous system disorders |
| US5935997A (en) * | 1998-01-13 | 1999-08-10 | Yukong Limited | O-thiocarbamoyl-aminoalkanol compounds, their pharmaceutically useful salts and process for preparing the same |
| CA2355293C (en) | 1998-12-23 | 2005-08-16 | Orphan Medical, Inc. | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
| CN1343219A (zh) * | 1999-01-28 | 2002-04-03 | 中外制药株式会社 | 取代的苯乙基胺衍生物 |
| CN1160329C (zh) * | 1999-02-05 | 2004-08-04 | Sk株式会社 | O-硫代氨基甲酰基-氨基烷醇化合物,其药学上认可的盐及其制备方法 |
| AU4403000A (en) * | 1999-04-23 | 2000-11-10 | Solvay Pharmaceuticals B.V. | Monomers and oligourea peptidomimetics and process for the prepa ration thereof |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| EP1264814A1 (en) * | 2001-06-08 | 2002-12-11 | Avantium International B.V. | Resolving agents based on amines |
| US6680299B2 (en) | 2001-07-27 | 2004-01-20 | Enanta Pharmaceuticals, Inc. | 4'-substituted leucomycins |
| KR100576372B1 (ko) * | 2001-08-03 | 2006-05-03 | 에스케이 주식회사 | Ｏ-티오카바모일-아미노알카놀 화합물, 이의 약학적 허용염 및 제조방법 |
| ITFI20030113A1 (it) * | 2003-04-24 | 2004-10-25 | Menarini Ricerche Spa | Composti lineari nk-2 antagonisti con caratteristiche basiche e formulazioni che li contengono. |
| CA2587481A1 (en) | 2004-10-28 | 2006-05-11 | Sk Corporation | Phenylalkylamino carbamates adjunctive therapy for depression |
| ES2435403T3 (es) * | 2005-06-08 | 2013-12-19 | Sk Biopharmaceuticals Co., Ltd. | Tratamiento de trastornos del sueño y vigilia |
| ES2344469T3 (es) | 2005-06-22 | 2010-08-27 | Sk Holdings Co., Ltd. | Tratamiento de disfuncion sexual. |
| CN101823987B (zh) * | 2009-03-06 | 2014-06-04 | 中国科学院上海药物研究所 | 一类新的dpp-ⅳ抑制剂及其制备方法和用途 |
| KR102173587B1 (ko) | 2009-06-22 | 2020-11-04 | 에스케이바이오팜 주식회사 | 피로의 치료 또는 예방 방법 |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| MX350745B (es) | 2009-11-06 | 2017-09-14 | Sk Biopharmaceuticals Co Ltd * | El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia. |
| US8895609B2 (en) | 2009-11-06 | 2014-11-25 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| CN102249833B (zh) * | 2011-05-27 | 2013-12-11 | 中国科学院化学研究所 | 一种制备手性γ-氨基酸及其衍生物的方法 |
| US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
| US9359290B2 (en) | 2013-03-13 | 2016-06-07 | Jazz Pharmaceuticals International Iii Limited | Treatment of cataplexy |
| CN110638805A (zh) | 2013-07-12 | 2020-01-03 | 爵士制药国际Iii有限公司 | 促进吸烟停止 |
| KR102309836B1 (ko) | 2013-07-18 | 2021-10-12 | 에스케이바이오팜 주식회사 | 비만의 치료 |
| WO2017007695A1 (en) * | 2015-07-09 | 2017-01-12 | The Regents Of The University Of California | Mu opioid receptor modulators |
| US10195151B2 (en) | 2016-09-06 | 2019-02-05 | Jazz Pharmaceuticals International Iii Limited | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
| EP4316592A3 (en) | 2016-10-06 | 2024-05-01 | Axsome Malta Ltd. | Carbamoyl phenylalaninol compounds and uses thereof |
| KR102643275B1 (ko) | 2017-07-31 | 2024-03-04 | 재즈 파마슈티칼즈 아일랜드 리미티드 | 카바모일 페닐알라니놀 유사체 및 이의 용도 |
-
2018
- 2018-07-31 KR KR1020207005652A patent/KR102643275B1/ko active Active
- 2018-07-31 WO PCT/US2018/044465 patent/WO2019027941A1/en not_active Ceased
- 2018-07-31 CA CA3071779A patent/CA3071779A1/en active Pending
- 2018-07-31 CN CN201880059970.5A patent/CN111094238B/zh active Active
- 2018-07-31 US US16/634,935 patent/US11413264B2/en active Active
- 2018-07-31 SG SG11202000817SA patent/SG11202000817SA/en unknown
- 2018-07-31 EP EP18840981.7A patent/EP3661911A4/en active Pending
- 2018-07-31 AU AU2018312328A patent/AU2018312328B2/en active Active
- 2018-07-31 JP JP2020505344A patent/JP7366002B2/ja active Active
- 2018-07-31 RU RU2020108634A patent/RU2020108634A/ru unknown
- 2018-07-31 MX MX2020001146A patent/MX2020001146A/es unknown
-
2020
- 2020-01-29 MX MX2023005484A patent/MX2023005484A/es unknown
- 2020-01-29 SA SA520411187A patent/SA520411187B1/ar unknown
-
2022
- 2022-06-16 US US17/841,976 patent/US20220401401A1/en not_active Abandoned
-
2023
- 2023-04-26 JP JP2023072520A patent/JP7642707B2/ja active Active
-
2024
- 2024-09-30 US US18/901,040 patent/US20250017890A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530837A5 (https=) | ||
| RU2020108634A (ru) | Аналоги карбамоилфенилаланинола и способы их применения | |
| JP2020503246A5 (https=) | ||
| FI3509582T3 (fi) | (r)-2-amino-3-fenyylipropyylikarbamaatin solvaattimuoto | |
| JP2007516941A5 (https=) | ||
| JP2007508361A5 (https=) | ||
| JP2017503000A5 (https=) | ||
| JP2014508811A5 (https=) | ||
| JP2016040288A5 (https=) | ||
| JP2016505637A5 (https=) | ||
| JP2014505107A5 (https=) | ||
| JP2007508360A5 (https=) | ||
| JP2009536161A5 (https=) | ||
| JP2017527578A5 (https=) | ||
| JP2015517574A5 (https=) | ||
| JP2008524262A5 (https=) | ||
| JP2017538689A5 (https=) | ||
| JP2019518770A5 (https=) | ||
| JP2019510082A5 (https=) | ||
| JP2009525312A5 (https=) | ||
| JP2013540712A5 (https=) | ||
| JP2016503010A5 (https=) | ||
| RU2015146417A (ru) | Пероральная фармацевтическая композиция для профилактики или лечения синдрома "сухого глаза", содержащая ребамипид или его предшественник | |
| JP2012526766A5 (https=) | ||
| JP2016501246A5 (https=) |